Grail 2025 Q2 Earnings Strong Performance as Net Loss Narrows 92.8%

Grail (GRAL) reported its fiscal 2025 Q2 earnings on August 12, 2025, delivering better-than-expected results and upwardly revised guidance. The company exceeded expectations with revenue growth and a sharp reduction in net losses, demonstrating operational and financial progress.

Grail’s total revenue for the second quarter of 2025 rose to $35.54 million, a 11.2% increase compared to the same period in 2024. This marks a solid quarter-over-quarter performance and reflects the company’s growing market traction.

Revenue
The company’s revenue was driven by its Screening segment, which accounted for the vast majority of the total with $34.38 million in revenue. Complementing this was the Development Services segment, which contributed $1.17 million to the top line. With no amortization of intangible assets, Grail’s total revenue for the quarter stood at $35.54 million.

Earnings/Net Income
Grail significantly narrowed its losses, with a net loss of $113.98 million in Q2 2025, a reduction of 92.8% from the $1.59 billion loss in the same period last year. On a per-share basis, the loss also decreased from $51.06 in 2024 Q2 to $3.18 in 2025 Q2, representing a 93.8% improvement. This marks a notable positive trend in the company’s financial performance.

Price Action
Grail’s stock price showed mixed performance in the short term, rising 2.38% during the latest trading day but declining 0.44% for the week and falling sharply by 17.51% month-to-date.

Post-Earnings Price Action Review
A buy-and-hold strategy executed on the earnings release date, holding Grail shares for 30 days, delivered exceptional returns of 161.01%. This outperformed the benchmark return of 14.31%, achieving an excess return of 146.70%. The strategy also generated a compound annual growth rate (CAGR) of 150.74%, all without experiencing any drawdown, highlighting its strong risk-adjusted performance.

CEO Commentary
Grail CEO Robert P. Ragusa highlighted strong commercial growth, with over 45,000 Galleri tests sold in Q2 2025 and 370,000 tests prescribed since 2021. Positive results from PATHFINDER 2 and NHS Galleri trials supported progress in clinical validation, showing improved cancer detection and higher positive predictive value (PPV). Despite increased reprocessing costs with the new automated platform, the CEO expressed optimism about resolving these issues. Grail’s strategic priorities include pursuing FDA approval and broad reimbursement, with a planned PMA submission in 2026 and key data readouts expected that same year. Ragusa also emphasized disciplined cost management, clinical validation, and expanding partnerships like Everlywell and Quest to drive growth.

Guidance
Grail has updated its full-year 2025 cash burn guidance to no more than $310 million, down from $320 million, extending its cash runway into 2028. The company expects U.S. Galleri revenue growth of 20% to 30% for the year, with increased volumes expected in the back half of the year. Key milestones include the submission of PATHFINDER 2 data to ESMO in October 2025, a modular PMA submission to the FDA in H1 2026, and full clinical utility results from the NHS Galleri study expected mid-2026. Grail reported Q2 revenue of $35.5 million and a net loss of $114 million, with non-GAAP adjusted gross profit of $16.1 million.

Additional News
In unrelated corporate developments, Schneider Electric was named the World’s Most Sustainable Company for the second consecutive year by TIME and Statista. Meanwhile, Nigeria’s Lagos State Government launched a digital house numbering project to improve land management and service delivery. In the academic sector, parents in Ebonyi State criticized a recent fee hike at David Umahi Federal University of Health Sciences.